ArticleAging2020

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.

Changyi Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.